

**MARKSANS PHARMA LIMITED**

Regd. Office:11th Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2011**

Rs.in Lacs

Sr. No.	PARTICULARS	For the Quarter ended on		For the year ended on
		30.6.2011 (UNAUDITED)	30.6.2010 (UNAUDITED)	31st March 11 (AUDITED)
1	Income			
	a>. Net Sales/ Income from Operations	7,353.64	7,204.86	30,531.80
	b>. Other Operating Income	5.20	31.14	175.06
	<b>Total Income</b>	<b>7,358.84</b>	<b>7,236.00</b>	<b>30,706.86</b>
2	Expenditure			
	a>. ( Increase)/Decrease in stock in trade	(2.17)	(207.62)	(45.33)
	b>. Consumption of Material & Purchases	4,526.47	5,029.87	20,324.89
	c>. Employee Cost	1,031.61	809.99	3,625.61
	d>. Depreciation	348.67	277.37	1,997.52
	e>. Other Expenditure	1,162.85	778.87	7,306.31
	<b>Total Expenditure</b>	<b>7,067.43</b>	<b>6,688.48</b>	<b>33,209.00</b>
3	Profit from Operations before other income			
	Interest & Exceptional Items (1-2)	291.41	547.52	(2,502.14)
4	Other Income	-	-	-
5	Profit before Interest & Exceptional item (3+4)	291.41	547.52	(2,502.14)
6	Interest	338.32	462.49	11,020.56
7	Profit after Interest but before Tax & Exceptional items	(46.91)	85.03	(13,522.70)
8	Exceptional items	-	-	-
9	<b>Profit/(Loss) from Ordinary activities before Tax (7+8)</b>	<b>(46.91)</b>	<b>85.03</b>	<b>(13,522.70)</b>
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	-	2.08	641.36
11	<b>Net Profit/(Loss) from Ordinary activities after tax(9-10)</b>	<b>(46.91)</b>	<b>82.95</b>	<b>(14,164.06)</b>
12	a>. Less::- Minority Interest	49.42	1.94	138.71
	b>. Less: Extraordinary Item-(Loss)/Profit on sale of API division/Fixed assets			(8,021.68)
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>(96.33)</b>	<b>81.01</b>	<b>(22,324.45)</b>
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.07	3,678.07	3,678.07
15	Reserve Excluding Revaluation Reserve as per Balance sheet of Previous Accounting year	-	-	6,216.30
16	a>. Earnings Per Share (Basic & Diluted) (before extraordinary items.Rs.)	(0.01)	0.02	(3.85)
	b>. Earnings Per Share( Basic & Diluted) (after Extraordinary items- Rs.)	(0.03)	0.02	(6.07)
17	Aggregate of Public Shareholding:			
	- Number of Shares	189,823,694	189,823,694	189,823,694
	- Percentage of Holding	51.61%	51.61%	51.61%
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510
	a>. Pledged/Encumbered			
	- Number of Shares	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A
	b>. Non-encumbered			
	- Number of Shares	177,983,510	177,983,510	177,983,510
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%

Sr. No.	Standalone Information	For the Quarter ended on		For the year ended on
		30.6.2011 (UNAUDITED)	30.6.2010 (UNAUDITED)	31st March 11 (AUDITED)
	Revenue	3,301.77	4,205.91	15,712.40
	Profit Before Tax from Ordinary activities	(30.09)	120.99	(13,272.61)
	Profit After Tax from Ordinary activities	(30.09)	120.99	(13,757.24)
	Profit After Tax after extraordinary item	(30.09)	120.99	(21,778.92)

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.08.2011
- 2 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 3 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 4 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 5 As reported earlier, the outstanding of principal value of Foreign Currency Convertible Bonds(The Bond) of USD 43,999,000, which have become due for redemption with redemption premium of USD 19,887,548, has not been redeemed.
- 6 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 7 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 8 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

**For MARKSANS PHARMA LIMITED**

Place: Mumbai.  
Date: 12.08.2011  
Visit us at [www.marksanspharma.com](http://www.marksanspharma.com)

**MARK SALDANHA**  
Managing Director.